WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke EXIANT wurde als Wortmarke am 03.10.2019 bei der Weltorganisation für geistiges Eigentum angemeldet.
| Markenform | Wortmarke |
| Aktenzeichen | 1537269 |
| Länder | 
|
| Basismarke |
Nr. 88381334,
11. April 2019
|
| Anmeldedatum | 03. Oktober 2019 |
| Ablaufdatum | 03. Oktober 2029 |
Markeninhaber
157 Technology Drive
Irvine CA 92618
US
Irvine CA 92618
US
Markenvertreter
P.O. Box 1135
Chicago IL 60690
US
Waren und Dienstleistungen
05
Pharmaceutical preparations for use in oncology;
pharmaceutical preparations for the treatment or prevention
of dermatological, cardiovascular, hematological, bone,
respiratory, central nervous system, endocrinological,
circulatory, gastroenterological, stomach, digestive,
hormonal, diabetic, muscular, rheumatic, immune system,
ocular and metabolic diseases and disorders; and for use in
oncology; diagnostic preparations and/or reagents for
clinical or medical laboratory use; pharmaceutical mineral
supplements and preparations
09
Downloadable software for the facilitation of communication,
namely, allowing patients and healthcare professionals to
access and share information in the medical, pharmaceutical
and health fields; downloadable software in the nature of a
mobile application for facilitation of communication,
namely, allowing patients and healthcare professionals to
access and share information in the medical, pharmaceutical
and health fields
10
Drug delivery devices in the nature of drug delivery
systems; drug delivery systems; injection device for
pharmaceutical preparations; injectors for medical purposes
in the nature of medical fluid injectors
35
Online wholesale services by direct solicitation by
salespersons directed to end-users featuring
pharmaceuticals; referral services in the field of treatment
for cancer, chemotherapy and pharmaceutical products in the
nature of medical referrals (terms too vague in the opinion
of the International Bureau – Rule 13 (2) (b) of the
Regulations); business administration of prescription drug
co-payment programs; business administration of patient
reimbursement programs; referral services in the field of
co-pay assistance programs in the nature of providing
insurance agent referrals (terms too vague in the opinion of
the International Bureau – Rule 13 (2) (b) of the
Regulations); providing an online commercial information
directory in the field of patient support featuring
information regarding healthcare providers, sites at which
subcutaneous injections could be administered and retail
pharmacies or specialty pharmacies where patients could
obtain pharmaceutical preparations
36
Providing healthcare administration, namely, providing
insurance verification and prior authorization services for
others (terms too vague in the opinion of the International
Bureau – Rule 13 (2) (b) of the Regulations)
41
Educational services, namely, development and dissemination
of printed educational materials of others in the fields of
pharmaceutical products and treatment of medical disorders;
conducting classes, seminars, conferences, and workshops in
the field of the use of prescription pharmaceutical products
for medical disorders, in the field of cancer, patient care;
educational and entertainment services, namely, providing a
motivational and educational speaker featuring information
regarding medical disorders; training services in the field
of patient support services relating to treatment of medical
disorders; providing on-line electronic newsletters
delivered by email, and blogs in the medical, pharmaceutical
and health fields
42
Medical and pharmaceutical research services; pharmaceutical
research and development
44
Patient support services relating to the treatment of
medical disorders, namely, providing online information in
the field of pharmaceutical preparations for treatment of
various diseases and providing medical consultancy and
advisory services via a global computer network; providing
health and medical information about medical disorders;
information services, namely, providing medical information
to cancer patients; providing patient support services
relating to cancer and cancer treatment in the nature of an
Internet-based database of patient medical information where
patients can inquire about medical issues and procedures
from other patients and can relay information about their
medical experiences for support and community; providing a
website featuring information in the medical and health
fields (terms too vague in the opinion of the International
Bureau – Rule 13 (2) (b) of the Regulations); providing a
website featuring information in the field of the
diagnostic, prophylactic and therapeutic properties of
pharmaceuticals (terms too vague in the opinion of the
International Bureau – Rule 13 (2) (b) of the Regulations);
providing information in the medical field and information
in the field of the diagnostic, prophylactic and therapeutic
properties of pharmaceuticals; providing health information;
providing patients with information in the medical field;
providing health information, namely, providing data on the
genetics and genetic sequencing of cancer tumors and cells;
genetic sequencing diagnostics and testing
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 08. Februar 2023 | 2023/13 Gaz | CA | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 09. Juni 2022 | 2022/25 Gaz | JP | RAW: No Effect Limitation |
| 04. April 2022 | 2022/15 Gaz | EM | RAW: No Effect Limitation |
| 24. März 2022 | 2022/13 Gaz | JP | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 24. Februar 2022 | 2022/11 Gaz | RAW: Limitation | |
| 14. Januar 2022 | 2022/3 Gaz | KR | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 19. November 2021 | 2021/47 Gaz | MX | Ablehnung |
| 02. November 2021 | 2021/48 Gaz | IL | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 21. Oktober 2021 | 2021/43 Gaz | CA | Ablehnung |
| 03. September 2021 | JP | Ablehnung | |
| 26. August 2021 | 2021/35 Gaz | JP | Ablehnung |
| 25. März 2021 | 2021/12 Gaz | KR | Ablehnung |
| 12. Februar 2021 | 2021/7 Gaz | GB | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 02. Februar 2021 | 2021/8 Gaz | EM | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 29. Oktober 2020 | 2020/45 Gaz | CN | Ablehnung |
| 30. September 2020 | 2020/41 Gaz | IL | Ablehnung |
| 29. September 2020 | 2020/42 Gaz | EM | Ablehnung |
| 17. Juli 2020 | 2020/30 Gaz | GB | Ablehnung |
| 15. Juli 2020 | 2020/31 Gaz | EM | Ablehnung |
| 03. Oktober 2019 | 2020/24 Gaz | US | Eintragung |
ID: 141537269